Journal
LUNG CANCER
Volume 54, Issue 2, Pages 243-245Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.lungcan.2006.07.017
Keywords
case reports; topotecan; camptothecins; antineoplastic agents; pulmonary fibrosis; lung diseases; interstitial; lung neoplasms; small cell lung cancer
Categories
Ask authors/readers for more resources
Drug-induced pulmonary toxicities of anticancer agents have been wet[ described, but the pathophysiology of agents typically used in advanced disease has not been well studied. Symptoms of pulmonary drug toxicity in advanced lung cancer patients may frequently be attributed to disease progression, pulmonary embolism, or infection. In patients with preexisting interstitial pulmonary fibrosis even less is known. This report describes an unfortunate patient with pre-existing pulmonary fibrosis and progressive extensive stage small cell lung cancer. After receiving a single intravenous dose of topotecan, the patient developed sub-acute respiratory failure, and died 15 days later with pathology findings of organizing, reparative phase, diffuse alveolar damage. To our knowledge this is the first pathology confirmation of diffuse alveolar damage in a patient developing dyspnea following topotecan therapy. The frequency with which camptothecin-related dyspnea is associated with diffuse alveolar damage might be underestimated and is of special concern in patients with limited pulmonary reserve. (C) 2006 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available